https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15021 Wed 11 Apr 2018 16:33:46 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:15126 Wed 11 Apr 2018 14:45:44 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18868 3 and 101–200 cells/mm3 were statistically significantly less likely to have virological failure, compared to those with a baseline CD4 count lower than 50 cells/mm ³ (OR=0.61, 95% CI 0.23–0.89; and OR=0.43, 0.18–0.78, respectively). In contrast, patients with a history of injecting drug use were statistically significantly more likely to have viraemia than otherwise (OR=1.32, 1.16–1.67). The PPV of the WHO immunological criteria was 60.1% (57.1–69.3%). Conclusions: Routine viral load tests should be conducted early to detect virological failure and prevent unnecessary changes to second-line treatments. To improve treatment outcomes, timely ART initiation and adherence to treatment among those with history of injecting drug use should be promoted.]]> Sat 24 Mar 2018 08:03:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17804 Sat 24 Mar 2018 07:57:36 AEDT ]]>